The freshly linked pair is chasing new drugs to treat undisclosed autoimmune diseases and also to improve conditioning regimens for sickle cell disease and beta thalassemia. More gentle conditioning ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Enlaza Therapeutics ("Enlaza" or the "Company"), the first covalent biologics platform company, today announced a ...

Vertex Pharmaceuticals (NASDAQ:VRTX) has had a rough month with its share price down 15%. However, stock prices ...

Vertex Pharmaceuticals commits $45 million upfront to leverage Enlaza Therapeutics’ War-Lock platform to create drug conjugates and T cell engagers for autoimmune diseases and gentler conditioning for ...

Enlaza Therapeutics partners with Vertex Pharmaceuticals to advance innovative therapies for autoimmune diseases using ...

Vertex Pharmaceuticals is partnering with California-based Enlaza Therapeutics in a deal aimed at advancing new conditioning ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $477.31, along with a high estimate of $553.00 and a low estimate of $405.00. Experiencing ...

Vertex Pharmaceuticals ( VRTX +0.01%) has been a top pharma stock in recent years. It has been generating strong revenue ...

A month has gone by since the last earnings report for Vertex Pharmaceuticals (VRTX). Shares have added about 6.9% in that time frame, outperforming the S&P 500. But investors have to be wondering, ...

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 1.09% to $396.62 Wednesday, on what proved to be an all-around mixed ...

Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage ...